NewsNewly-Approved European Hemp Seeds To Deliver Record Levels Of...

Newly-Approved European Hemp Seeds To Deliver Record Levels Of CBD


BULGARIAN firm CBD Seed Europe has secured a place on the European seed register for two of its genetics which it says deliver record levels of cannabidiol.

Whilst most registered CBD seeds on the European Common Catalogue deliver CBD contents of 5% to 6% its newly-registered varieties can reach up to 12% in the field.

The two new registered varieties are know as ‘Midwest’ and ‘Northwest’ will be viable at most latitudes across the continent, says the company. 

And, with the EC limits for THC content in hemp seeds set to rise from 0.2% to 0.3% it says it will be able to develop new strains that will raise the CBD level ‘even higher’

€500,000 Investment

Americo Folcarelli, co-founder of CBD Seed Europe, said its success is the result of substantial work and investment.

“We are delighted that after after two years of trials and research – and over €500,000 of investment – we have reached the stage where our two high-CBD seed varieties have been approved for sale in the European Union.

“We believe this opens up a number of unique business opportunities including the exploration of joint ventures with other breeders in order to create new strains specifically designed for the European market.“

CBD Seeds Europe worked closely with the European Industrial Hemp Association (EIHA) to bring forward its new strains.

CBD Seed’s Bulgarian hemp field

EIHA Managing Director Lorenza Romanese said: “We are certainly happy that finally EU breeders are able to provide to EU farmer’s varieties which are adapted to our climate and richer in CBD – this is what the market has been asking for.”

CBD Seed Europe was founded by Canadian cannabis entrepreneur Mr Folcarelli and his Bulgarian business partner Ivailo Staninski, with the business being run by Simeon Genov.

In 2021 it says its recorded revenues of €500,000 and is projecting future annual sales of €4m as a result of this new development.

Huge Growth Potential

Mr Folcarelli says he was attracted to the European cannabis and CBD market by its growth potential and, after running into numerous bureaucratic challenges in Southern Europe, the company settled on Bulgaria.

After two years of testing under the auspices of the Bulgarian Seed Agency, as specified by EU guidelines, its two new genetics officially debuted on the on the European Catalogue last month. 

With Bulgaria now the company’s home – it was instrumental in founding the Bulgarian Industrial Hemp Association – it has plans to build the world’s first EU-GMP seed and genetics research facility over the next 12 months.  

CBD Seed’s research facilities

“It is my vision that we can create a fully-functional and vertically-integrated supply chain from genetics all the way to consumer products – so that every product is traceable right back to the seeds that started the process.

“This will allow us to create new and better hybrids to rival and surpass those being created in other parts of the world,” he said.

The company is keen on working with European partners to support the industry’s growth.

Partnership’s ‘Vital

He added: “Along with seed registration we have also worked the Bulgarian Ministry of Agriculture, alongside EIHA, to help them develop regulations and legislation so that farmers and processors can go about their work legally and securely. 

“Along with our partners and collaborators we are also working with government agencies in Greece, Italy and Spain to have better regulation and transparency at all levels of the supply chain to ensure to the final consumer that they are getting safe and effective products.”  

With much imported US biomass delivering CBD content at up to 15% this latest development will boost the competitiveness of the European industry.

Although Mr Folcarelli contends that some North American biomass does not adhere to the ‘required EU-GMP standards and should not be allowed in food supplements’.

The global hemp seed market was valued at US$830m in 2021 and is expected to reach US$1,550m by 2027

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

PRESS RELEASE TILRAY Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and...

Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses

AMID the economic chaos that dominated the headlines over the past week, nearly half-a-dozen UK-based or UK-listed cannabis companies...

MGC Pharma Announces Appointment Of UK Advisor And New COO/Deputy CEO

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development...

Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest

LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total...

European Cannabis Stocks Review: £22m Wiped From LSE-Listed Cannabis Stocks Amid Market Chaos

FOLLOWING a few weeks of relative positivity for many of the stocks listed on the London Stock Exchange (LSE),...

German SPD Representatives Confident A Solution To International Legal Hurdles Will Be Found

EARLIER this month news broke that recent analysis conducted by the Bundestag's scientific service suggested the creation of a...

Must read

You might also likeRELATED
Recommended to you